Related Experiment Video

Updated: May 31, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

Non-small-cell lung carcinoma vaccines in clinical trials

Antonio Rossi1, Paolo Maione, Clorinda Schettino

  • 1Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.

Expert Review of Vaccines
|June 23, 2011
PubMed

Insights

Cancer vaccines for non-small-cell lung cancer (NSCLC) show promise by targeting tumor antigens. Despite past setbacks, ongoing clinical trials are re-evaluating vaccine therapy for NSCLC treatment.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Non-small-cell lung cancer (NSCLC) is generally considered non-immunogenic.
  • However, NSCLC may present a targetable vulnerability for a stimulated immune system.
  • Generating effective anti-tumor immune responses in NSCLC patients has been a significant challenge.

Purpose of the Study:

  • To review Phase I, II, and III clinical trials of cancer vaccines for NSCLC.
  • To assess the potential of vaccine therapy in NSCLC treatment.
  • To provide an outlook on the future of NSCLC vaccine strategies.

Main Methods:

  • Review of published and ongoing clinical trials (Phase I-III) for NSCLC vaccines.
  • Analysis of preclinical and early-phase clinical data.
  • Discussion of patient selection and immune response assessment methodologies.

Main Results:

  • No specific active cancer vaccine has been approved for NSCLC to date, despite promising early data.
  • Previous trial failures may be attributed to patient selection and immune assessment issues.
  • Vaccine therapy is re-emerging as a viable therapeutic avenue.

Conclusions:

  • Cancer vaccines represent a potential future approach for NSCLC treatment.
  • Further research and optimized trial designs are crucial for vaccine development in NSCLC.
  • Identifying lung tumor antigens and optimal antigen presentation are key for effective immune priming.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...